Search
Mobile menu Mobile menu
Product Management , AI Strategy , Med Tech Nov 17, 2026

Medical Device AI Integration Is About to Get Crowded: What the Insulin Pump Market Signals for Health Tech Platform Strategy

VECTOR Labs Team
VECTOR Labs Team
Medical Device AI Integration Is About to Get Crowded: What the Insulin Pump Market Signals for Health Tech Platform Strategy
Last updated on: Nov 17, 2026

When multiple competing AI-assisted insulin delivery platforms receive regulatory clearance within a narrow window, the diabetes care community notices. Health system CTOs and health tech platform engineers should notice for a different reason entirely. What is happening in the tubeless insulin pump segment is an early, visible instance of a pattern that will repeat across cardiology, neurology, and remote monitoring: AI-enabled hardware-software bundles proliferating simultaneously, each generating proprietary data streams, each carrying its own algorithmic logic, and none of them designed to talk cleanly to your existing infrastructure.

The strategic question is not which device performs best clinically. That is a procurement and clinical informatics question. The strategic question is what happens to your platform architecture when three incompatible closed-loop systems are all generating glucose, insulin, and activity data inside the same patient population, and your EHR, your analytics layer, and your care coordination tools are expected to make sense of all of it.

Companion piece to our broader work on regulated AI in medical devices. See Why AI Quality Systems in MedTech Are the Next Regulatory Flashpoint for Enterprise Deployments for a practical guide to FDA enforcement patterns and remediation architecture.

The Fragmentation Is Structural, Not Incidental

Competing platforms do not fragment because vendors are being difficult. They fragment because the regulatory pathway for AI-enabled medical devices rewards vertical integration. A closed-loop insulin delivery system earns its clearance as a complete system: the sensor, the pump, the algorithm, and the data pipeline are validated together. Separating any layer from the others potentially invalidates the safety case.

This means vendors have a regulatory incentive to keep the stack closed. Opening the algorithm to third-party inputs, or exposing raw sensor data to external systems, introduces variables the original submission did not account for. The result is that each cleared platform becomes a walled garden, not because of commercial strategy alone, but because openness creates regulatory surface area.

For health system technology leaders, this is the mechanism worth understanding. The fragmentation you will encounter is not a temporary market condition that will resolve when standards mature. It is a structural property of how AI-enabled devices are currently cleared.

What Data Lock-In Looks Like in Practice

Proprietary Schemas and Limited Export

Each platform will offer some form of data export or API access, typically scoped to what the vendor controls and formatted to their own schema. Time-series glucose data from one platform will not share field names, resolution, or units conventions with a competitor's output without transformation. At small scale this is a normalisation problem. Across a patient population using three or four different systems, it becomes a persistent integration tax.

The deeper issue is that the algorithmically derived outputs, the dosing recommendations, the trend predictions, the alert thresholds, are not raw sensor data. They are the product of a proprietary model running on proprietary inputs. If your analytics platform ingests those outputs without understanding the model's assumptions, you are building downstream clinical logic on top of a black box you do not control and cannot audit.

Algorithm Accountability Gaps

This is where the risk concentrates. When a care coordination tool surfaces a recommendation that traces back through a chain of vendor algorithms, the accountability question becomes genuinely difficult. Which system's logic produced the signal? What were the training data characteristics? What patient subgroups were underrepresented in validation?

Health systems that have not established a framework for algorithm accountability before these devices proliferate will find themselves answering those questions reactively, under clinical or regulatory pressure, rather than by design.

Integration Architecture Decisions You Need to Make Now

The practical architecture question is where in your stack you absorb the heterogeneity. There are two coherent positions, and a third that looks like a strategy but is not.

The first position is to build a device-agnostic normalisation layer that ingests vendor data, transforms it to a canonical internal schema, and strips out vendor-derived algorithmic outputs in favour of your own downstream models. This preserves analytical consistency and keeps your platform's clinical logic auditable. The cost is that you lose the vendor's proprietary signal, which may have genuine clinical value.

The second position is to treat each device ecosystem as a distinct data product, maintain separate pipelines, and accept that cross-device population analytics will require explicit reconciliation steps. This is operationally heavier but preserves fidelity to each vendor's validated outputs. It is the more defensible position if your platform is downstream of clinical decision-making rather than generating it.

The third position, ingesting everything into a unified data lake and deferring the schema and accountability questions, is not a strategy. It is a liability accumulation exercise.

Vendor Dependency and Procurement Leverage

Health systems that negotiate device contracts without reference to data portability terms are accepting a dependency they may not be able to exit. Once a patient cohort is established on a platform, the switching cost is clinical as well as technical. Migrating patients between closed-loop systems carries real continuity-of-care risk, which gives vendors structural negotiating leverage at renewal.

The time to establish data portability requirements is before deployment, not after. This means procurement processes for AI-enabled medical devices need technical input from platform engineering teams, not just clinical and commercial stakeholders. The questions that matter include: what export formats are supported, what is the API access model, what happens to historical data if the contract ends, and what commitments exist around schema stability across firmware updates.

These are not novel questions in enterprise software procurement. They are simply not yet standard practice in medical device procurement, and that gap is where the dependency risk accumulates.

What a Coherent Platform Strategy Looks Like

A coherent strategy has three components. The first is a classification policy: a documented position on which device data streams your platform will ingest, in what form, and what algorithmic outputs you will treat as inputs versus generate internally. This does not need to be resolved for every device category today, but it needs to exist as a framework before your next device integration decision.

The second component is an algorithm accountability register. For every AI-derived signal your platform surfaces to clinicians or uses in downstream logic, there should be a record of its origin, its validation scope, and the conditions under which it should not be trusted. This is the internal equivalent of the technical file a medical device manufacturer maintains, applied to your platform's use of external AI outputs.

The third component is a vendor engagement model that treats data architecture as a first-class procurement criterion. Clinical performance, regulatory status, and commercial terms are already standard evaluation dimensions. Data portability, schema documentation, and API governance need to be added alongside them.

The insulin pump market is fragmented now and will become more so. The health systems and platform teams that build these frameworks while the market is still relatively small will be in a substantially better position when the same dynamic plays out across a dozen other device categories over the next three to five years.

Where Vector Labs Fits

We build and certify AI systems for regulated medical device environments, with direct experience navigating the validation and documentation requirements that shape integration architecture decisions. In our cardiovascular certification work, we delivered a Class 2A certified AI model for wearable ECG atrial fibrillation detection within a commercial product launch timeline, with validation structured from the outset to meet medical device software standards. If you are working through device data integration strategy or algorithm accountability frameworks for your platform, contact us at vector-labs.ai/contacts.

FAQs

Why can't we just use the vendor API and treat device data like any other third-party integration?

You can treat the data transport layer that way, but the clinical accountability layer requires more. When a vendor API returns an algorithmically derived dosing recommendation or risk score, your platform is consuming the output of a validated medical device algorithm. If your system then uses that output to generate further clinical logic, you may be operating outside the vendor's validated use case and potentially within the scope of Software as a Medical Device regulation yourself. The integration decision has regulatory implications that a standard third-party API relationship does not.

How should we handle patients using multiple competing devices across our population?

The practical minimum is a canonical internal schema that normalises time-series physiological data across devices, with explicit tagging of which fields are raw sensor outputs versus vendor-derived algorithmic outputs. Population-level analytics should be built on the normalised layer, not on vendor-specific outputs, unless you can document and defend the assumption that those outputs are clinically equivalent across platforms. In most cases that equivalence has not been established, and treating them as interchangeable introduces an unacknowledged source of analytical error.

At what point does our platform's use of device AI outputs make us a SaMD manufacturer?

The threshold is whether your platform uses device-derived data to generate outputs that are intended to influence clinical decision-making in their own right. Displaying a vendor's cleared output to a clinician is generally within the vendor's regulatory scope. Combining outputs from multiple devices to generate a new clinical recommendation, or feeding device data into your own model to produce a risk score, is more likely to constitute a distinct SaMD function. The analysis depends on your specific architecture and intended use, but the question should be answered explicitly before you build, not after you ship.

What contractual terms should we prioritise when procuring AI-enabled medical devices?

Data portability on contract termination, schema versioning commitments tied to firmware and algorithm updates, API access scope and rate limits, and audit rights over algorithm change notifications are the four areas with the most downstream platform impact. Schema instability is a particularly common problem: vendors update their algorithms as part of normal post-market surveillance, and those updates can silently change the meaning of fields your integration depends on. A contractual requirement for advance notification of algorithm updates, with a defined change management window, protects your platform's analytical integrity over the contract lifetime.

Is there an emerging standard for medical device data interoperability that will resolve this over time?

HL7 FHIR Device and Observation resources provide a framework for representing device-generated data in a standardised format, and adoption is growing in EHR integration contexts. However, FHIR standardises the transport and representation layer, not the semantic meaning of algorithmically derived outputs. Two devices can both export FHIR-compliant data while their underlying algorithmic outputs remain clinically incomparable. Standards work will reduce the integration friction over time, but it will not resolve the algorithm accountability question, which requires platform-level governance regardless of what transport standards the market converges on.

A team that understands you
With 20+ years of experience in the world's leading consultancy companies, implementing AI and ML projects in industry-specific contexts, we are ready to hear your challenges.
Subscribe to our newsletter for insights and updates on AI and industry trends.
By clicking "Sign me up", you agree to our Privacy Policy.
By clicking the Accept button, you are giving your consent to the use of cookies when accessing this website and utilizing our services. To learn more about how cookies are used and managed, please refer to our Privacy Policy and Cookies Declaration